SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-053618
Filing Date
2020-11-12
Accepted
2020-11-12 16:41:43
Documents
61
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-10q_20200930.htm 10-Q 1589807
2 EX-31.1 lrmr-ex311_12.htm EX-31.1 12460
3 EX-31.2 lrmr-ex312_10.htm EX-31.2 12586
4 EX-32.1 lrmr-ex321_7.htm EX-32.1 14194
  Complete submission text file 0001564590-20-053618.txt   6008839

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT lrmr-20200930.xml EX-101.INS 1179476
6 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20200930.xsd EX-101.SCH 53431
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lrmr-20200930_cal.xml EX-101.CAL 49432
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lrmr-20200930_def.xml EX-101.DEF 146827
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20200930_lab.xml EX-101.LAB 411421
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20200930_pre.xml EX-101.PRE 297798
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 201307427
SIC: 2834 Pharmaceutical Preparations